The identification of AREG as a key mediator in pulmonary fibrosis has prompted the development of targeted therapeutic strategies aimed at selectively inhibiting AREG signaling while avoiding the broad toxicities associated with general EGFR or TGF-β pathway inhibition. This evidence concerns the gene TGFB1 and pulmonary fibrosis.